3-(isocyanatomethyl)pyridine | 71189-18-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3-(isocyanatomethyl)pyridine
• 英文别名: pyridin-3-yl-methyl isocyanate
• CAS: 71189-18-9
• 化学式: C₇H₆N₂O
• 分子量: 134.137
• InChiKey: LNTLNDGJZJWLGG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  42.3
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(isocyanatomethyl)pyridine 在 硫酸 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 乙腈 为溶剂， 反应 6.0h， 生成 11-[(4-Methoxyphenyl)methyl]-5-(pyridin-3-ylmethyl)-3,5,7,9,11,13-hexazatricyclo[8.3.0.02,6]trideca-1(10),2,6,8,12-pentaen-4-one
  参考文献：
  名称：

  Structure-based drug design and potent anti-cancer activity of tricyclic 5:7:5-fused diimidazo[4,5-d:4′,5′-f][1,3]diazepines

  摘要：

  Judicial structural modifications of 5: 7-fused ring-expanded nucleosides (RENs), based on molecular modeling studies with one of its known targets, human RNA helicase (hDDX3), led to the lead, novel, 5:7-5-fused tricyclic heterocycle (1). The latter exhibited promising broad-spectrum in vitro anti-cancer activity against a number of cancer cell lines screened. This paper describes our systematic, albeit limited, structure-activity relationship (SAR) studies on this lead compound, which produced a number of analogs with broad-spectrum in vitro anti-cancer activities against lung, breast, prostate, and ovarian cancer cell lines, in particular compounds 15i, 15j, 15m and 15n which showed IC50 values in submicromolar to micromolar range, and are worthy of further explorations. The SAR data also enabled us to propose a tentative SAR model for future SAR efforts for ultimate realization of optimally active and minimally toxic anti-cancer compounds based on the diimidazo[4,5-d:4',5'-f][1,3]diazepine structural skeleton of the lead compound 1. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.11.050
• 作为产物：
  描述：

  3-吡啶乙酸 在 叠氮磷酸二苯酯 、 三乙胺 作用下， 以 甲苯 为溶剂， 反应 1.25h， 生成 3-(isocyanatomethyl)pyridine
  参考文献：
  名称：

  Structure-based drug design and potent anti-cancer activity of tricyclic 5:7:5-fused diimidazo[4,5-d:4′,5′-f][1,3]diazepines

  摘要：

  Judicial structural modifications of 5: 7-fused ring-expanded nucleosides (RENs), based on molecular modeling studies with one of its known targets, human RNA helicase (hDDX3), led to the lead, novel, 5:7-5-fused tricyclic heterocycle (1). The latter exhibited promising broad-spectrum in vitro anti-cancer activity against a number of cancer cell lines screened. This paper describes our systematic, albeit limited, structure-activity relationship (SAR) studies on this lead compound, which produced a number of analogs with broad-spectrum in vitro anti-cancer activities against lung, breast, prostate, and ovarian cancer cell lines, in particular compounds 15i, 15j, 15m and 15n which showed IC50 values in submicromolar to micromolar range, and are worthy of further explorations. The SAR data also enabled us to propose a tentative SAR model for future SAR efforts for ultimate realization of optimally active and minimally toxic anti-cancer compounds based on the diimidazo[4,5-d:4',5'-f][1,3]diazepine structural skeleton of the lead compound 1. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.11.050

文献信息

• Compounds useful as reversible inhibitors of cysteine proteases
  申请人：——

  公开号：US20020058809A1

  公开（公告）日：2002-05-16

  Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of the formulas (I), (II), (Ia) and (Ib) further defined herein. The compounds are useful for treating autoimmune diseases. Also disclosed are processes for making such novel compounds. 1

  揭示了新型的cathepsin S、K、F、L和B可逆抑制化合物的化学式(I)、(II)、(Ia)和(Ib)，进一步在此处进行了定义。这些化合物可用于治疗自身免疫性疾病。还公开了制备这种新型化合物的方法。
• 双苯基脲类化合物及其药物组合物、制备方法及用途
  申请人：中国药科大学

  公开号：CN111848506B

  公开（公告）日：2023-01-31

  本发明公开了双苯基脲类化合物及其药物组合物、制备方法及用途。本发明的双苯基脲类化合物及其药物组合物对VEGFRs以及NAMPT具有很好的抑制活性，对肿瘤细胞的生长具有较好的抑制作用。
• 一种新型NAMPT和IDO双重抑制剂及其制 备方法和医药用途
  申请人：药康众拓（江苏）医药科技有限公司

  公开号：CN108530444B

  公开（公告）日：2021-08-24

  本发明公开了一种新型NAMPT和IDO双重抑制剂及其制备方法和医药用途，具体涉及一种呋咱类化合物或其药学上可接受的盐、溶剂化物、前药、酯、外消旋体和异构体和含有这类化合物的药物组合物以及这些化合物或药物组合物在制备抗肿瘤药物中的应用。本发明将IDO抑制剂和NAMPT抑制剂的活性片段进行合理拼接得到了呋咱类IDO/NAMPT双靶点抑制剂，一方面双重抑制了NAD+的生物合成，从而表现出更强的肿瘤抑制活性；另一方面IDO活性的抑制可以有效地促进T细胞的增殖，从而增强机体对肿瘤细胞的攻击能力。这类呋咱类IDO/NAMPT双靶点抑制剂或其药物组合物具有广阔的应用前景，有望成为抗肿瘤药物。
• BROAD-SPECTRUM NON-COVALENT CORONAVIRUS PROTEASE INHIBITORS
  申请人：Purdue Research Foundation

  公开号：US20170313685A1

  公开（公告）日：2017-11-02

  This invention pertains to materials and methods for the treatment of patients with coronavirus infection and the control of zoonotic disease outbreaks using broad-spectrum non-covalent coronavirus protease inhibitors.

  这项发明涉及利用广谱非共价冠状病毒蛋白酶抑制剂治疗冠状病毒感染患者以及控制人畜共患病爆发的材料和方法。
• 吲哚酮类化合物及其药物组合物、制备方法及用途
  申请人：中国药科大学

  公开号：CN113717159A

  公开（公告）日：2021-11-30

  本发明公开了如通式I所示结构的吲哚酮类化合物及其药物组合物、制备方法及用途。本发明的苯并吲哚酮类化合物对VEGFRs以及NAMPT具有很好的抑制活性，对肿瘤有良好的治疗作用。